Firms

dRx Capital

Basel, Switzerland (original JV headquarters and later brand location) · Cambridge, Massachusetts, United States (published brand office) · San Francisco, California, United States (historical JV office)

drxcapital.com

linkedin.com

dRx Capital is a digital-health and life-sciences technology investment brand, originally launched in2015 through dRx Capital AG, a Swiss joint venture between Novartis and Qualcomm. It backs data and digital technologies including healthcare AI, machine learning, research tools, precision medicine, clinical-trial platforms, pharmaceutical commercialization and neurological digital therapies such as Cala Health’s wearable neuromodulation. The original AG dissolved in July2021: Science37’s SEC filing confirms its interests were distributed to its two50% owners. That legal event does not establish that the dRx brand ceased: subsequent Novartis and portfolio-company primary sources describe Novartis dRx Capital as its digital-health venture program, and the FutureHealth2026 organizer lists Rana Lonnen as its Managing Director. Earlier partners are separately qualified as historical. The initial venture program was announced with up toUSD100million in capital commitments; no undisclosed final close, current AUM or new third-party fund is inferred. Verified portfolio includes Aktana, Science37, Cala Health, Flywheel, Omada and other data-driven healthcare businesses. This profile preserves historical JV and later brand context without claiming that the dissolved AG is an active legal issuer or merging it with Novartis Venture Fund or Qualcomm Ventures.

Founded: 2015
Type: Venture capital

Funds1

dRx Capital 2015 joint-venture investment program2015-01-122015-01-12—
Original Swiss Novartis–Qualcomm digital-medicine venture program. Announced January12,2015 with up toUSD100M commitment, and described in original2015–2016 issuer releases as aUSD100M fund. No primary final fund-close statement or realized fundraising amount verified; structured amount remains NULL. Original dRxCapitalAG dissolved July2021, with interests distributed to its two50% owners; no replacement LP fund invented.

Team

Operations and support

Aaron NelsonGeneral Partner / Investor (historical)

Carolyne ZimmermannFounding Member; General Partner (historical)

Eric BoutinManaging Director (historical; former by 2025)

Jack YoungGeneral Partner; JV launch leadership (historical)

Lucian IancoviciGeneral Partner (historical 2015–2017)

Neil TiwariPrincipal; Managing Director / General Partner (historical 2017–2021)

Rana LonnenManaging Director — Novartis dRx Capital (publicly listed 2026)

Thomas KluzGeneral Partner (historical)

$40M2022-06-09	Peptone	Andrew Hedin, dRx Capital
$100M2021-11-16	H1	Flex Capital, Lux Capital, dRx Capital
$25M2021-11-09	Mekonos	S32, TDK Ventures, Sands Capital, Imaginary Ventures, TDR Capital, ICU Ventures, Section 32, dRx Capital
$33M2021-09-20	Tact Ai	dRx Capital
$12M2021-06-22	Nuvoair	Kaya VC, Christoph Ruedig, dRx Capital
$58M2020-12-17	H1	Y Combinator, Transformation Capital, Menlo Ventures, Institutional Venture Partners, Lux Capital, Lead Edge Capital, dRx Capital
$2M2020-11-17	Peptone	dRx Capital
$40M2020-08-20	Science 37	Lux Capital, dRx Capital
$50M2019-05-21	Cala Health	dRx Capital
$35M2019-03-01	Science 37	dRx Capital
$29M2017-04-25	Science 37	Lux Capital, dRx Capital
$31M2016-10-18	Science 37	Lux Capital, dRx Capital
$6M2015-10-20	Science 37	dRx Capital, Lux Capital
$48M2015-09-16	Omada Health	Casper de Clercq, dRx Capital
$—Unknown date	Vineti	dRx Capital
$—Unknown date	Aktana	dRx Capital
$—Unknown date	Freenome	EcoR1 Capital, dRx Capital
$15M2021-02-03	Flywheel.io	Francisco Gimenez, dRx Capital
$23M2021-01-07	Aspen RxHealth	Steve Kraus, dRx Capital
$—Unknown date	Pear Therapeutics	dRx Capital

dRx Capital

Funds1

Team

Operations and support

Co-investing

Investments